

Correction to Discovery of Potent Keap1–Nrf2 Protein–Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis

Zheng-Yu Jiang, Meng-Chen Lu, Li-Li Xu, Ting-Ting Yang, Mei-Yang Xi, Xiao-Li Xu, Xiao-Ke Guo, Xiao-Jin Zhang, Qi-Dong You,* and Hao-Peng Sun*

Journal of Medicinal Chemistry **2014**, *57*, 2736–2745. DOI: 10.1021/jm5000529

Pages 2736–2745. In the paper, the BLI (biolayer interferometry) result of **2** was calculated only from two concentrations. It may not reflect the binding affinity of **2** correctly. The concentrations of **2** in the BLI assay were adjusted, and the experiment was repeated many times. The K_d value of **2** calculated from the four concentrations for the dose–response curves (Figure 7D) was 9.91 nM. Thus, the K_d value of **2** should be corrected as being 9.91 nM instead of 3.59 nM. Additionally, we found that when Keap1 was treated with compound **2**, the decline of the BLI response at high concentration of compound **2** (especially when the concentration was above 100 nM) was inevitable.

Although the value is slightly different from that determined from the two-concentration BLI response curve in the original paper, they just diversified in the same order of magnitude. The correction of the BLI assay has no significant effect on our experimental results, nor does it change the conclusions of the paper.




Figure 7. (D) BLI dose–response curves of **2** (concentrations: 80.0, 40.0, 20.0, 10.0 nM).